Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 14/20 | 0.55 |
| ▸ | NPC1 | O15118 | 10/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295245 | 0.87 | ADORA2A (0.53) | RAB9ANPC1MEN1KMT2APOLB | |
| SCHEMBL18969626 | 0.84 | RAB9A (0.57) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL16607118 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL4293279 | 0.81 | RAB9A (0.60) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3194666 | 0.79 | ADORA2A (0.75) | SMN1; SMN2RAB9ANPC1ADORA2AADORA1 | |
| SCHEMBL233270 | 0.79 | SMN1; SMN2 (0.75) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL22440671 | 0.77 | RAB9A (0.60) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL10253092 | 0.76 | SMN1; SMN2 (0.71) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL16594526 | 0.76 | SMN1; SMN2 (0.71) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL4290502 | 0.76 | SMN1; SMN2 (0.71) | SMN1; SMN2RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | claimed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | claimed |
| CN-1870996-A | N-thiazol-2-yl-benzamide derivatives | LUNDBECK & CO AS H (DK) | 2006-11-29 | — | — | CN | claimed |
| EP-1682129-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-07-26 | — | — | EP | claimed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | claimed |
| WO-2005039572-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-05-06 | — | — | WO | claimed |
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-10-01 | — | — | US | disclosed |
| EP-1803455-A1 | N-thiazol-2-yl-benzamide derivatives | H.Lundbeck A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| EP-1682129-B1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2007-02-21 | — | — | EP | disclosed |
| CN-1870996-A | N-thiazol-2-yl-benzamide derivatives | LUNDBECK & CO AS H (DK) | 2006-11-29 | — | — | CN | disclosed |
| EP-1682129-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-07-26 | — | — | EP | disclosed |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | H. LUNDBECK A/S (DK) | 2006-07-13 | — | — | US | disclosed |
| WO-2005039572-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247593-A1 | N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 1617/4885RAB9A 2380/4885NPC1 1022/4885 |
| US-20060154974-A1 | N-thiazol-2-yl-benzamide derivatives | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 1617/4885RAB9A 2380/4885NPC1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.